Weight Loss Drugs and Insurance Realities | Science News

New weight loss drugs like Ozempic and Wegovy are revolutionizing obesity treatment, but insurers are stuck in a cost crunch. While studies prove their health benefits, covering even a fraction of users could hit insurance budgets with over $800 million. The promise? Preventing future health costs by tackling obesity early. But here’s the catch: long-term data is lacking, and most patients quit within a year—often due to cost or side effects—leading to weight regain. For insurers to see real savings, patients need sustained support: dietitians, gym access, and lifestyle coaching. Without that full package, the pills alone won’t cut it—and insurers won’t pay for the whole system. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/7b627d8012010756